Two-drug combo aims to shrink esophageal tumors before surgery
NCT ID NCT07191977
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This phase 2 trial tests whether giving camrelizumab (an immunotherapy) and palbociclib (a targeted therapy) before surgery can safely shrink tumors in people with esophageal squamous cell carcinoma that can be removed. About 41 adults aged 18-75 with resectable cancer will receive the drug combination, then have surgery. The main goal is to see how many patients have a major reduction in tumor cells after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUR CELL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.